WaveMan
WaveMan · Company
ARQT · Arcutis Biotherapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ARQT Arcutis Biotherapeutics (ARQT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001787306
Quote by TradingView
Congress · 1Form 144 · 13
Insider buyers, 180 days
0
Funds added, last quarter
137
13F, latest reported quarter
Conversions, 180 days
20
Codes C/M, not in net · $542.2K priced

What the filings say about ARQT

Insiders, 180 days
-$3.2M net sold
7 sellers · 15% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: purchase, 2026-05-29
Planned sales (Form 144), 90 days
$12.8M
13 notices

Arcutis Biotherapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Arcutis Biotherapeutics, Inc. insiders sold a net $3.2M of stock across 299 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Welgus Howard G.
Director
SELL
2026-10-19 SECtraded 2026-10-15
4,728
$127.3K
-3.5%
Context
  • 52 earlier Form 4 trades (code P or S) here by this insider (52 sales), the last on Sep 15, 2026.
  • The trade is 13.4% of the 35,207 shares held after it.
  • 1 other insider sold within 30 days.
  • 137 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Welgus Howard G. sold about $127.3K of ARQT under a 10b5-1 plan on Oct 15, 2026; 1 other insider sold within 30 days and 137 funds added in the latest 13F quarter.
Matsuda Masaru
See Remarks
SELL
2026-09-18 SECtraded 2026-09-16
3,674
$91.9K
+22.0%
Context
  • 37 earlier Form 4 trades (code P or S) here by this insider (2 buys, 35 sales), the last on Sep 8, 2026.
  • +20.9% median (+20.9% mean) 90-day return after 2 previous buys.
  • The trade is 3.3% of the 112,508 shares held after it.
  • 3 other insiders sold within 30 days.
  • 137 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Matsuda Masaru sold about $91.9K of ARQT under a 10b5-1 plan on Sep 16, 2026; 3 other insiders sold within 30 days and 137 funds added in the latest 13F quarter.
Welgus Howard G.
Director
SELL
2026-09-17 SECtraded 2026-09-15
4,730
$114.4K
+24.8%
Context
  • 51 earlier Form 4 trades (code P or S) here by this insider (51 sales), the last on Aug 17, 2026.
  • The trade is 13.2% of the 35,841 shares held after it.
  • 3 other insiders sold within 30 days.
  • 137 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Welgus Howard G. sold about $114.4K of ARQT under a 10b5-1 plan on Sep 15, 2026; 3 other insiders sold within 30 days and 137 funds added in the latest 13F quarter.
Matsuda Masaru
See Remarks
SELL
2026-09-10 SECtraded 2026-09-08
9,989
$250.0K
+32.6%
Context
  • 36 earlier Form 4 trades (code P or S) here by this insider (2 buys, 34 sales), the last on Aug 3, 2026.
  • +20.9% median (+20.9% mean) 90-day return after 2 previous buys.
  • The trade is 8.6% of the 116,182 shares held after it.
  • 3 other insiders sold within 30 days.
  • 137 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks Matsuda Masaru sold about $250.0K of ARQT under a 10b5-1 plan on Sep 8, 2026; 3 other insiders sold within 30 days and 137 funds added in the latest 13F quarter.
Curran Terrie
Director
SELL
2026-08-28 SECtraded 2026-08-27
11,148
$279.0K
+32.2%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 20, 2026.
  • The trade is 47.4% of the 23,526 shares held after it.
  • 4 other insiders sold within 30 days.
  • 137 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Curran Terrie sold about $279.0K of ARQT on Aug 27, 2026; 4 other insiders sold within 30 days and 137 funds added in the latest 13F quarter.
299 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 294 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$3.2M over 180 days
-$2.3M over 90 days
below 74% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
137 funds bought in last quarter
more than 79% of Pharma & Biotech
Revenue
+123.4% year over year
more than 86% of Pharma & Biotech
Margin
-4.3% net margin
more than 70% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
23.1% of the float short (float per yahoo 2026-10-26) · 4.8 days to cover · settled 2026-09-30
more than 90% of Pharma & Biotech
What changed in the last 30 days
Oct 20Former Officer Larry Todd Edwards filed to sell $2.0M by Oct 20 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 19Director Welgus Howard G. sold $127.3K under a 10b5-1 plan (Oct 15)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 15Director Howard Welgus filed to sell $127.3K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch ARQT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+57.8%12M
-3%+19%+41%+63%2025-102025-122026-022026-042026-062026-082026-10 2025-11-24 · Watanabe Todd sold $1.5M2025-10-28 · Watanabe Todd sold $1.0M2026-03-02 · Leonard Keith R sold $997.1K2026-03-02 · Watanabe Todd sold $912.8K2025-11-13 · Krishnamohan Neha sold $910.7K2025-11-24 · LIN SUE-JEAN sold $777.9K2025-11-06 · Edwards Larry Todd sold $732.9K2026-08-27 · Curran Terrie sold $677.1K2026-02-02 · Watanabe Todd sold $505.7K2026-02-02 · Matsuda Masaru sold $489.1K2025-11-20 · Gilbert Halley E sold $455.5K2025-11-06 · Burnett Patrick sold $417.1K2025-12-15 · Burnett Patrick sold $332.8K2025-12-01 · Welgus Howard G. sold $302.1K2026-01-02 · Welgus Howard G. sold $289.6K2025-11-03 · Watanabe Todd sold $283.6K2026-08-27 · Curran Terrie sold $279.0K2026-03-02 · Welgus Howard G. sold $256.5K2026-02-04 · Burnett Patrick sold $252.8K2025-11-03 · Welgus Howard G. sold $252.7K2026-02-02 · Welgus Howard G. sold $250.5K2026-09-08 · Matsuda Masaru sold $250.0K2026-04-01 · Welgus Howard G. sold $238.8K2026-08-11 · Burnett Patrick sold $220.1K2026-02-02 · Matsuda Masaru sold $213.8K2026-02-02 · Matsuda Masaru sold $203.6K2025-11-03 · Matsuda Masaru sold $177.0K2026-08-12 · Burnett Patrick sold $174.8K2026-05-04 · Matsuda Masaru sold $171.5K2026-03-02 · Matsuda Masaru sold $164.9K2026-05-01 · Welgus Howard G. sold $164.2K2026-03-02 · Burnett Patrick sold $153.6K2026-10-15 · Welgus Howard G. sold $127.3K2026-07-15 · Welgus Howard G. sold $127.3K2026-08-17 · Welgus Howard G. sold $123.8K2026-02-02 · Matsuda Masaru sold $120.8K2026-06-15 · LIN SUE-JEAN sold $120.6K2026-09-15 · Welgus Howard G. sold $114.4K2026-08-03 · Watanabe Todd sold $114.3K2026-06-15 · Welgus Howard G. sold $100.0K2026-02-02 · Burnett Patrick sold $93.7K2026-02-27 · Matsuda Masaru sold $92.9K2026-10-20 · Larry Todd Edwards filed to sell $2.0M2026-10-15 · Howard Welgus filed to sell $127.3K2026-09-16 · Larry Todd Edwards filed to sell $8.5M2026-09-15 · Howard Welgus filed to sell $114.4K2026-09-08 · Masaru Matsuda filed to sell $341.9K2026-08-27 · Terrie Curran filed to sell $956.1K2026-08-20 · Terrie Curran filed to sell $27.9K2026-08-19 · Patrick Burnett filed to sell $45.8K2026-08-17 · Howard Welgus filed to sell $123.8K2026-08-11 · Patrick Burnett filed to sell $397.8K2026-08-03 · Patrick Burnett filed to sell $24.9K2026-08-03 · Todd Frank Watanabe filed to sell $114.3K2026-08-03 · Matsuda Masaru filed to sell $32.1K2026-07-15 · Howard Welgus filed to sell $127.3K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ARQT: institutional holders (13F)

13F holdings, latest reported quarter
MONTANOVA CAPITAL, LLC
12,437,000 sh
$326.1M
BlackRock, Inc.
10,545,466 sh
$276.5M
Frazier Life Sciences Management, L.P.
9,874,511 sh
$258.9M
Rubric Capital Management LP
8,271,577 sh
$216.9M
Polar Capital Holdings Plc
6,606,945 sh
$173.2M

Congress trades in ARQT

STOCK Act disclosures, US House only, filed up to 45 days after the trade
Gilbert Cisneros
Bought 2026-05-29 · disclosed 10 days later
$1,001 - $15,000
Gilbert Cisneros
Bought 2026-03-03 · disclosed 35 days later
$1,001 - $15,000
Gilbert Cisneros
Sold 2025-12-11 · disclosed 32 days later
$1,001 - $15,000
All stocks members of Congress are buying · Every member's trades

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ARQT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Larry Todd Edwards
Filed 2026-10-20
$2.0M
Howard Welgus
Filed 2026-10-15
$127.3K
Larry Todd Edwards
Filed 2026-09-16
$8.5M
Howard Welgus
Filed 2026-09-15
$114.4K
Masaru Matsuda
Filed 2026-09-08
$341.9K

ARQT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
abrdn Focused U.S. Small Cap Active ETF
$214.7K position · as of 2026-07-31
2.1%
abrdn U.S. Small Cap Equity Fund
$6.8M position · as of 2026-07-31
1.7%
Invesco Dorsey Wright Healthcare Momentum ETF
$3.6M position · as of 2026-07-31
1.5%
Virtus Biotech Etf
$1.5M position · as of 2026-07-31
1.5%
Global X Guru Index ETF
$894.8K position · as of 2026-07-31
1.5%
Lazard US Small Cap Equity Select Portfolio
$502.0K position · as of 2026-06-30
1.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
18 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
1 active
7
Phase 2
0 active
7
Phase 3
0 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Todd Franklin Watanabe
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.2M
$20.4M
$2.4M
+3%
+20%
2024
$3.7M
$11.2M
$2.7M
-50%
-9%
2023
$4.9M
-$1.2M
$1.6M
-89%
-8%
2022
$4.6M
$2.4M
$2.3M
-47%
-11%
2021
$4.8M
$441.9K
$3.1M
-26%
-1%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $3.2M sold by insiders over 180 days, 137 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $12.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ARQT financials

Revenue growth
+123.4%
XBRL, annual
Net margin
-4.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$464.0M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+6.1%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$39.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.49x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.36x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
+15.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+6.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
+11.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
150.86x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$4.1B
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
+1.0%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$376.1M$196.5M$59.6M$3.7M
Operating income-$12.2M-$128.4M-$241.1M-$301.6M
Net income-$16.1M-$140.0M-$262.1M-$311.5M
EPS (diluted)-0.13-1.16-3.78-5.66
Operating cash flow-$5.6M-$112.2M-$247.1M-$257.7M
Cash$42.9M$71.3M$88.4M$53.6M
Long-term debt$108.0M$107.2M$201.8M$197.8M
SEC XBRL, fiscal years, as known on 2026-10-28

ARQT Stock Sonar score 6/7 axes

Find similar shapesCompare

ARQT ranks highest on profitability (88th percentile) and growth (86th), and lowest on insider conviction (13th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
88
Inputs
  • Return on equity+15.9% · 87 pct, sector of 545
  • Return on assets+6.8% · 87 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed+11.9% · 91 pct, sector of 576
Financial health
59
Inputs
  • Debt to equity0.49x · 32 pct, sector of 352
  • Cash flow to debt0.36x · 86 pct, sector of 371
Growth
86
Inputs
  • Revenue growth, YoY+123.4% · 86 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
13
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.6M · 26 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
56
Inputs
  • Funds adding, latest quarter137 · 79 pct, sector of 698
  • Congress net buyers, 365d0 · 33 pct, sector of 49
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
37
Inputs
  • Short interest, % of float+23.1% · 10 pct, sector of 813
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+7.9% · 64 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ARQT filings, in plain words

Are Arcutis Biotherapeutics insiders buying or selling ARQT?

In the 180 days to 2026-10-28, Arcutis Biotherapeutics insiders were net sellers, a net $3.2M across purchases and sales reported on Form 4, by 7 sellers.

Have members of Congress traded ARQT?

Yes. In the year to 2026-10-28, 1 House member disclosed buying ARQT and 1 House member disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-05-29.

Are there planned insider sales of ARQT?

Yes. 13 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $12.8M of stock; the latest, by Larry Todd Edwards, was filed 2026-10-20.

Read the full summary

In the 180 days to 2026-10-28, Arcutis Biotherapeutics insiders were net sellers of ARQT, a net $3.2M across purchases and sales reported on Form 4 by 7 sellers. 15% of the 26 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-28, 1 member of Congress disclosed buying ARQT and 1 member disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-05-29. Insiders filed 13 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $12.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies